Key Takeaway: Nurix is showcasing its commitment to developing innovative therapies at the ASH Event 2023. The company emphasizes its focus on translating scientific insights into effective treatments for cancer and autoimmune diseases. Their portfolio includes both wholly owned and partnered assets, highlighting a collaborative approach to drug development.
Price reaction · baseline $8.41 (2023-12-11 close) · hit pre-market · 1 other NRIX headline(s) in the window, move may be shared
day 0 close · peak
-1.4%
Market Sentiment Analysis
POSITIVE FACTORS
Nurix is focused on translating scientific insights into therapies.
The company has a multi-modal portfolio targeting cancer and autoimmune diseases.
They are advancing both wholly owned and partnered assets.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What is the focus of Nurix at the ASH Event 2023?
Nurix is focused on translating scientific insights into innovative therapies.
What diseases does Nurix target?
Nurix targets cancer and autoimmune diseases with its therapies.
What type of portfolio does Nurix have?
Nurix has a multi-modal portfolio of wholly owned and partnered assets.